OCM
SPRY icon

Osterweis Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Osterweis Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1K Sell
2,637
-2,973
-53% -$25.6K ﹤0.01% 218
2026
Q1 		$45K Hold
5,610
– – ﹤0.01% 198
2025
Q4 		$65.4K Buy
+5,610
New +$54.6K ﹤0.01% 193

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Osterweis Capital Management's SPRY Position: Q2 2026 in Review

Osterweis Capital Management reduced its ARS Pharmaceuticals (SPRY) stake by 53% in Q2 2026, selling an estimated $25.6K and leaving 2,637 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #218.

Osterweis Capital Management first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. The position peaked at $65.4K in Q4 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Osterweis Capital Management held 2,637 shares of ARS Pharmaceuticals worth $21.1K as of Q2 2026.
  • Osterweis Capital Management sold 2,973 ARS Pharmaceuticals shares in Q2 2026, an estimated $25.6K.
  • ARS Pharmaceuticals made up ﹤0.01% of Osterweis Capital Management's portfolio in Q2 2026, its #218 holding.
  • Osterweis Capital Management first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Osterweis Capital Management's ARS Pharmaceuticals position peaked at $65.4K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Osterweis Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.